CymaBay Therapeutics, Inc.
CymaBay Therapeutics, Inc. (CBAY): 2 pipeline candidates · ~43 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
42.5 months
D/E 0.49 · 0% dilution
Lead: Phase 2
2 candidates
N/A
N/A
A transparent, data-derived signal for CymaBay Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$207.0M
Quarterly Burn
$27.4M
Runway
42.5 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
| Drug | Phase |
|---|---|
| mbx-2982 | Phase 2 |
| seladelpar | Phase 2 |
Frequently asked questions
How many drug candidates are in CymaBay Therapeutics, Inc.'s pipeline?
CymaBay Therapeutics, Inc. (CBAY) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is CymaBay Therapeutics, Inc.'s lead drug candidate?
CymaBay Therapeutics, Inc.'s most advanced tracked candidate is mbx-2982 (Phase 2) for Hypoglycemia in Type 1 Diabetics.
What is CymaBay Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, CymaBay Therapeutics, Inc. has approximately 42.5 months of cash runway.
Who is the CEO of CymaBay Therapeutics, Inc.?
Janet Dorling is the chief executive officer of CymaBay Therapeutics, Inc. (CBAY).
Get the full picture on CymaBay Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.